Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7639813 | 0.96 | ACP3 (0.48) | ACP3TDP1MCL1CETPMTNR1A | |
| SCHEMBL8520737 | 0.93 | ACP3 (0.53) | ACP3TDP1MCL1CETPMTNR1A | |
| SCHEMBL7605396 | 0.82 | ACP3 (0.63) | ACP3TDP1FFAR1AKR1B1CYP1A2 | |
| SCHEMBL3245338 | 0.80 | SRC (0.61) | TDP1CETPSRCL3MBTL1 | |
| SCHEMBL7053859 | 0.78 | ACP3 (0.43) | ACP3TDP1MCL1MTNR1ACTNNB1 | |
| SCHEMBL5057873 | 0.75 | FOLH1 (0.43) | ACP3TDP1MCL1FFAR1AKR1B1 | |
| SCHEMBL5054433 | 0.75 | ACP3 (0.43) | ACP3TDP1MCL1MTNR1ASLC16A3 | |
| SCHEMBL28278348 | 0.74 | ACP3 (0.44) | ACP3TDP1MTNR1AFFAR1AKR1B1 | |
| SCHEMBL5059954 | 0.74 | ACP3 (0.44) | ACP3TDP1MCL1MTNR1AFFAR1 | |
| SCHEMBL27494073 | 0.74 | TDP1 (0.46) | ACP3TDP1MCL1MTNR1AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |